16 Matching Annotations
  1. Last 7 days
    1. (highland Papua New Guinea tribes, uncontacted Amazonian communities, Sentinelese, interior Maasai/Mongolian herders/Bedouin still on traditional raw dairy only)

      cut

    2. Analysed in aggregate, dairy shows no association: total dairy was null in the Ausimmune case-control (Dieu 2022, PMID 35645978) and total dairy was null in a UK MS-register analysis of disease activity (Temperley 2023, PMID 38130338

      repetition with slightly different meaning

    3. The signal appears only when milk form is stratified; aggregate-dairy measures yield inconsistent signals across cohorts (null in Ausimmune, protective in three Iranian case-controls, elevated in Sepčić Croatia) consistent with the weighted form-mix in each population

      Repeated below

    Annotators

  2. Apr 2026
    1. Author context (determines optimal strategy). No institutional affiliation, no career or funding dependency, no active need to establish publication priority against parallel work. Goal 1 (per CLAUDE.md) is patient-directed evidence; Goal 2 is publishable hypothesis paper as a "nice to have." Strategy is calibrated to this profile — specifically NOT optimized for impact factor, career metrics, or priority racing.

      Delete

    1. If fenebrutinib is not yet available, should ocrelizumab/rituximab be reconsidered as a bridge? (Previously declined, Sep 2025)

      why are we asking this question? we dont think this is a good idea right? and the doctor didnt think so before either.